COVID-19 treatment clinical trial underway

The first clinical trial of a potential COVID-19 treatment involving a discovery by Hudson Institute researchers received approval in September.

Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson Institute
Dr Michael Gantier

An end-stage prostate cancer drug will be tested as a treatment in COVID-19 patients in Europe, following a discovery by Dr Michael Gantier and his team that the drug has potent anti-inflammatory activity.

The trial will involve approximately 40 patients in hospitals in Ukraine and Moldova, two countries experiencing high rates of SARS-CoV-2 infection and hospitalisation.

Dr Gantier and his team discovered in laboratory tests that the active ingredient in the anti-cancer drug Veyonda, idronoxil, could block the production of several pro-inflammatory proteins, known as cytokines.

These proteins are involved in the ‘cytokine storm’ or hyper-inflammation that leads to life threatening acute respiratory distress and death from COVID-19. By stopping this reaction, the severity of the infection and any potential long-term impacts of COVID-19 could be reduced.

Contact us

Hudson Institute communications
t: + 61 3 8572 2697
e: communications@hudson.org.au

Research Group leading this work